DNLI vs PH · $2.11B cap vs P/E 28, rev $19.85B
Denali Therapeutics Inc (DNLI) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported DNLI revenue for 2024-12-31 was $0. Net income was -$422.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. DNLI currently screens at market cap $2.11B.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
DNLI currently screens at market cap $2.11B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the DNLI and PH stock pages for the full models.
Not investment advice.